Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Verona Pharma (VRNA – Research Report). The company’s ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, and Vertex Pharmaceuticals are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech ...

Vertex Pharmaceuticals has dominated the cystic fibrosis (CF) market and is now expanding into new, high-growth areas. The ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

The cell-based product is a nicotinamide modified allogeneic hematopoietic progenitor cell therapy that was FDA-OK'd and launched in 2023.

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Vertex Pharmaceuticals trades at $500.94 and has moved in lockstep with the market. Its shares have returned 5.5% over the ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Every year, amid Women’s History Month, March 8 marks International Women’s Day—a day dedicated to both honoring past efforts ...